"10.1371_journal.pone.0053297","plos one","2013-01-04T00:00:00Z","Diego Cadavid; Stephanie Jurgensen; Sophia Lee","MS Clinical Development Group, Biogen Idec, Cambridge, Massachusetts, United States of America; MS Global Medical Affairs, Genzyme, a Sanofi Company, Cambridge, Massachusetts, United States of America; Biometrics, Biogen Idec, Cambridge, Massachusetts, United States of America","Conceived and designed the experiments: DC SL SJ. Performed the experiments: SJ. Analyzed the data: SL SJ DC. Wrote the paper: DC SL SJ.","The authors have the following interests. DC and SL are employees of Biogen Idec Inc. SJ was an employee of Biogen Idec Inc. at the time that manuscript development began; she is currently with Genzyme, a Sanofi company. The IMPACT trial was funded by Biogen Idec Inc.; the other trials were funded by Biogen Idec Inc. in partnership with Elan Pharmaceuticals, Inc. Editorial support for preparation of the manuscript was funded by Biogen Idec Inc. and Elan Pharmaceuticals, Inc. Biogen Idec is the maker of Tysabri® (natalizumab) and Avonex® (intramuscular interferon beta-1a). There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2013","01","Diego Cadavid","DC",3,TRUE,3,1,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
